Who Created Mounjaro, and What Makes It Different?

Which company made Mounjaro, and why did they develop it?

Eli Lilly and Company developed Mounjaro. Lilly is one of the oldest pharmaceutical firms in the world, and its endocrinology research has long focused on diabetes and metabolic disease. Tirzepatide grew out of that work, scientists noticed that the hormone GIP, alongside the better-known GLP-1, played a meaningful role in blood-sugar regulation and appetite. Rather than target only GLP-1 (as earlier injectable treatments do), Lilly's researchers engineered a single molecule that binds to both receptors. The result was tirzepatide, a molecule whose origins and early development history are covered in detail on the page about when tirzepatide was created.

The medicine received its first approval for type 2 diabetes in the US in 2022, then in the UK. Its weight-management licence in the UK followed as trial data from the SURMOUNT programme accumulated. You can trace the timeline in more detail on the page covering when Mounjaro was created.

Lilly sources Mounjaro into the UK through an authorised supply chain, and the brand trades here under Lilly's UK operations. If you want to understand the broader story of tirzepatide as a molecule rather than a brand, the page on who created tirzepatide covers the research lineage in full.

What did Lilly's clinical trials actually show?

The SURMOUNT-1 trial is the headline study. It randomised 2,539 adults with obesity (without diabetes) to tirzepatide or placebo over 72 weeks. At the 15mg maintenance dose, participants achieved an average body-weight reduction of around 20–21%, with some analyses reaching approximately 22.5%. These figures are drawn from the trial paper published in the New England Journal of Medicine and form the basis of NICE's appraisal. NICE reviewed that evidence and issued technology appraisal TA1026 in December 2024, recommending tirzepatide for adults with a BMI of 35 or above alongside at least one weight-related health condition.

Results varied by dose, as you would expect from a titrated medicine, the 5mg and 10mg doses produced meaningful but lower average losses. Lilly also ran SURMOUNT-2 (adults with obesity and type 2 diabetes) and the head-to-head SURMOUNT-5 trial against semaglutide 2.4mg, which found greater average weight reduction with tirzepatide over 72 weeks. These are not small studies, the SURMOUNT programme involved thousands of participants across multiple countries.

What the trials measured was average outcomes in controlled conditions alongside a reduced-calorie diet and increased activity. Individual results vary, and no prescriber can promise a specific figure for any one person.

How does the dual-receptor mechanism actually work?

GLP-1 (glucagon-like peptide-1) slows the stomach's emptying rate and signals fullness to the brain. Most injectable weight-loss medicines work here alone. Tirzepatide adds a second action: it also binds to GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is released from the small intestine after eating and plays a role in both energy storage and appetite regulation. Activating both pathways together appears to produce a stronger appetite-suppressing effect than either pathway alone, which is one reason the SURMOUNT-1 results were larger than those seen in GLP-1-only trials.

The NHS patient-level overview of tirzepatide on the NHS website explains the mechanism in accessible terms and also covers the most common side effects, which are predominantly gastrointestinal (nausea, loose stools, indigestion) most noticeable after starting or after a dose step, and usually settling as the body adjusts.

For patients thinking about how this interacts with diet, the question of what to eat on Mounjaro is one our prescribers are asked regularly. Protein adequacy, fibre and hydration matter more than most people expect once appetite is substantially reduced.

How does Lilly's supply chain connect to a UK private prescription?

In the UK, Mounjaro is dispensed only against a valid prescription issued by a qualified prescriber. Lilly supplies the medicine through authorised pharmaceutical wholesalers to GPhC-registered pharmacies, the same regulated pathway that covers any dispensed medicine in Britain. A pharmacy you cannot verify on the GPhC register sits outside that chain entirely, and the MHRA has warned repeatedly about counterfeit pens sold online that have contained harmful substitutes.

At nume, our GPhC-registered pharmacy (registration number 9012878) sources Mounjaro through Lilly's authorised UK supply chain. Every order is reviewed by a GPhC-registered Independent Prescriber before dispatch, not software, a named clinician. The pen arrives via tracked DPD delivery in plain packaging, refrigerated for the journey; it goes straight into the fridge door when it arrives, just as it would from any registered pharmacy.

If cost is part of your thinking, the Mounjaro price page sets out what private treatment typically involves and what to look for in a transparent quote. For a broader look at licensed weight-loss options, the weight-loss treatments overview is a good starting point.